semaglutide chemical structure | GLP-1 receptor agonist | 910463-68-2 Semaglutide TFA | 50000+ Bioactive

RENAL IMPAIRMENT: No dose adjustment required for renal impairment, but monitor closely in severe renal impairment due to dehydration risk from GI side effects

Kidney disease and increased mortality risk in type 2 diabetes

Clinical review: Regulation of food intake, energy balance, and body fat mass: implications for the pathogenesis and treatment of obesity

So it makes perfect sense that GLP-1 medications, which can lead to weight loss, have become part of this conversation

Both medications may cause nausea, vomiting, and diarrhea

Apart from resmetirom, recently approved by the FDA for use in patients with MASH with moderate to advanced liver fibrosis, there are no other therapeutic options for this disease 92